This study is for people with a type of skin cancer called melanoma, specifically at stage IIIB or IIIC. The purpose is to see if a new treatment called Daromun, given before surgery (*neoadjuvant*), helps patients live longer without the cancer coming back (*recurrence-free survival*). Some patients will get Daromun, surgery, and after-treatment (*adjuvant therapy*), while others will have surgery and after-treatment only. The study will follow patients for up to six years to track their health.

• Participation could last up to six years with several follow-up visits.
• The study is open-label, meaning patients and doctors know the treatment given.
• Participants need to meet certain health criteria to join.

Inclusion means you are at least 18 years old, have a specific stage of melanoma that can be surgically removed, and meet other health requirements (like certain blood levels). Exclusion means you cannot join if you have other severe health issues, allergies to treatment components, or have had specific recent treatments. Participants will be randomly assigned to one of the two study groups, and local approved after-treatments are allowed.